Article

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination

2021-02-11

Abstract excerpt

<h4>SUMMARY</h4> The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa) and B.1.1.248 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and conf...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8aa20c50-b149-5015-9ff5-fa4686b2cfda
DOI: 10.1101/2021.02.11.430787

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccinationDOI 10.1101/2021.02.11.430787Read

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodiesSemantic proximity Read

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.Semantic proximity Read

SARS CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination seraSemantic proximity Read

Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccinationSemantic proximity Read

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variantSemantic proximity Read

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.Semantic proximity Read

Antibody evasion by the P.1 strain of SARS-CoV-2.Semantic proximity Read

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited seraSemantic proximity Read

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesSemantic proximity Read

Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited seraSemantic proximity Read

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesSemantic proximity Read

TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)Semantic proximity Read